Endogena Therapeutics, Inc.

Endogena Therapeutics, Inc. is a biotechnology startup based in Switzerland, focusing on the discovery and development of first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Founded in 2016, the company's slogan "endogena’s mission is to discover and develop endogenous regenerative medicines to repair and regenerate tissues" aligns with its ambitious goals in disrupting the field of regenerative medicine.

Their innovative approach integrates the latest developments in stem cell biology, artificial intelligence, and expertise in small-molecule drug design to address unmet medical needs associated with aging and genetic diseases. Recently, the company secured a significant $21.00M Series A investment on 13 December 2021 from Defta Partners and Rejuveron Life Sciences, affirming the investor confidence in the potential of their breakthrough treatments for degenerative diseases.

Endogena Therapeutics' novel drug discovery approach focuses on the selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules. Their ability to harness the potential of adult stem- and precursor cells, combined with state-of-the-art innovation, positions the startup as a promising player in the regenerative medicine landscape, with a vision to drive a paradigm change in medical treatment.